Published on Linksbridge News on September 22, 2021
Mentions: AMR, INCATE, Novo Holdings, CARB-X, Boehringer Ingelheim, Roche, Shionogi
September 22, 2021 — A new nonprofit dubbed the Incubator for Antibacterial Therapies in Europe (INCATE) will support the European-based development of novel therapies, diagnostics and interventions to combat antimicrobial resistance. A Novo Holdings REPAIR Impact Fund director announced the incubator’s launch Sunday in a LinkedIn post.
INCATE’s support, a mix of consulting, business networking, and up to approximately $290,000 in non-dilutive funding (for selected projects), aims to bring companies to “an investable stage of interest” that might attract larger backers like the Novo Holdings fund and CARB-X.
Industry partners include Boehringer Ingelheim, Roche and Shionogi, according to INCATE’s website.
Novo Holdings REPAIR Impact Fund post